Compare Incyte Corporation (INCY) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United Microelectronics Corp — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while United Microelectronics Corp trades at $19.35 (market cap $47.81B). The key difference: United Microelectronics Corp is the larger of the two by market cap, and United Microelectronics Corp pays a 2.12% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | UMC | |
|---|---|---|
Market Cap | $24.54B | $47.81B |
Sector | Health | Technology |
52-Week High | $129.93 | $28.02 |
52-Week Low | $81.61 | $6.58 |
Enterprise Value | $20.04B | $44.93B |
Dividend Yield | — | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
UMC trades at $19.50, up 3.78% today, with neutral technical signals and strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 expectation. Recent announcements include fab expansions in Singapore and Taiwan to meet AI-driven demand, supported by growing silicon photonics production. Valuation metrics show a P/E of 18.55 and P/S of 6.02, with robust profitability margins including 32.75% net income margin.
Outlook remains positive with projected revenue growth to $250.7B in 2026 and net income rebound to $82.1B. Key risks include semiconductor cycle volatility and execution challenges from capacity expansion. Analyst consensus shows mixed sentiment with 26.7% buy ratings versus 20% sell recommendations, suggesting cautious optimism amid expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
